Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review
-
- Kurahashi Kiyoe
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Endo Itsuro
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Kondo Takeshi
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Morimoto Kana
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Yoshida Sumiko
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Kuroda Akio
- Diabetes Therapeutics and Research Center, Tokushima University, Japan
-
- Aihara Ken-ichi
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Matsuhisa Munehide
- Diabetes Therapeutics and Research Center, Tokushima University, Japan
-
- Nakajima Kohei
- Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
-
- Mizobuchi Yoshifumi
- Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
-
- Nagahiro Shinji
- Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
-
- Abe Masahiro
- Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
-
- Fukumoto Seiji
- Institute of Advanced Medical Sciences, Fujii Memorial Institute of Medical Sciences, Tokushima University, Japan
この論文をさがす
抄録
<p>Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 56 (18), 2455-2461, 2017
一般社団法人 日本内科学会